title: Consensus guidelines for the management and treatment of neuroendocrine tumors.
abstract: Neuroendocrine tumors are a heterogeneous group of tumors originating in various anatomic locations. The management of this disease poses a significant challenge because of the heterogeneous clinical presentations and varying degrees of aggressiveness. The recent completion of several phase 3 trials, including those evaluating octreotide, sunitinib, and everolimus, demonstrate that rigorous evaluation of novel agents in this disease is possible and can lead to practice-changing outcomes. Nevertheless, there are many aspects to the treatment of neuroendocrine tumors that remain unclear and controversial. The North American Neuroendocrine Tumor Society published a set of consensus guidelines in 2010, which provided an overview for the treatment of patients with these malignancies. Here, we present a set of consensus tables intended to complement these guidelines and serve as a quick, accessible reference for the practicing physician.
authors.affiliation: Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305-5826, USA pkunz@stanford.edu
authors.forename: Pamela L
authors.initials: PL
authors.lastname: Kunz
authors.forename: Diane
authors.initials: D
authors.lastname: Reidy-Lagunes
authors.forename: Lowell B
authors.initials: LB
authors.lastname: Anthony
authors.forename: Erin M
authors.initials: EM
authors.lastname: Bertino
authors.forename: Kari
authors.initials: K
authors.lastname: Brendtro
authors.forename: Jennifer A
authors.initials: JA
authors.lastname: Chan
authors.forename: Herbert
authors.initials: H
authors.lastname: Chen
authors.forename: Robert T
authors.initials: RT
authors.lastname: Jensen
authors.forename: Michelle Kang
authors.initials: MK
authors.lastname: Kim
authors.forename: David S
authors.initials: DS
authors.lastname: Klimstra
authors.forename: Matthew H
authors.initials: MH
authors.lastname: Kulke
authors.forename: Eric H
authors.initials: EH
authors.lastname: Liu
authors.forename: David C
authors.initials: DC
authors.lastname: Metz
authors.forename: Alexandria T
authors.initials: AT
authors.lastname: Phan
authors.forename: Rebecca S
authors.initials: RS
authors.lastname: Sippel
authors.forename: Jonathan R
authors.initials: JR
authors.lastname: Strosberg
authors.forename: James C
authors.initials: JC
authors.lastname: Yao
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism; D006801:Humans; D058990:Molecular Targeted Therapy; D018358:Neuroendocrine Tumors / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D009656:North America; D012955:Societies, Medical
chemical_list: D014408:Biomarkers, Tumor